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Summary
The Cardiovascular Autonomic Neuropathy (CAN) Subcommittee of the
Toronto Consensus Panel on Diabetic Neuropathy worked to update CAN
guidelines, with regard to epidemiology, clinical impact, diagnosis, usefulness
of CAN testing, and management. CAN is the impairment of cardiovascular
autonomic control in the setting of diabetes after exclusion of other causes.
The prevalence of confirmed CAN is around 20%, and increases up to 65%
with age and diabetes duration. Established risk factors for CAN are gly-
caemic control in type 1 and a combination of hypertension, dyslipidaemia,
obesity, and glycaemic control in type 2 diabetes. CAN is a risk marker
of mortality and cardiovascular morbidity, and possibly a progression pro-
moter of diabetic nephropathy. Criteria for CAN diagnosis and staging are:
(1) one abnormal cardiovagal test result identifies possible or early CAN;
(2) at least two abnormal cardiovagal test results are required for definite
or confirmed CAN; and (3) the presence of orthostatic hypotension in addi-
tion to abnormal heart rate test results identifies severe or advanced CAN.
Progressive stages of CAN are associated with increasingly worse prognosis.
CAN assessment is relevant in clinical practice for (1) diagnosis of CAN
clinical forms, (2) detection and tailored treatment of CAN clinical correlates
(e.g. tachycardia, orthostatic hypotension, non-dipping, QT interval prolon-
gation), (3) risk stratification for diabetic complications and cardiovascular
morbidity and mortality, and (4) modulation of targets of diabetes therapy.
Evidence on the cost-effectiveness of CAN testing is lacking. Apart from the
preventive role of intensive glycaemic control in type 1 diabetes, recommen-
dations cannot be made for most therapeutic approaches to CAN. Copyright
 2011 John Wiley & Sons, Ltd.
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Introduction
This consensus document on diabetic cardiovascular autonomic neuropathy
(CAN) is the work product of the CAN Subcommittee of the Toronto Consen-
sus Panel on Diabetic Neuropathy. The aims were to (1) update the current
guidelines on the assessment and management of CAN [1]; (2) revise the
data on epidemiology and clinical impact of CAN [2,3]; (3) propose uniform
and standardized diagnostic modalities for CAN; (4) evaluate the clinical
usefulness of autonomic testing in diabetes in terms of its cost-effectiveness
and potential impact on outcomes; (5) propose sensitive and reproducible
measures of CAN to be used as end-points in prospective observational and
Copyright  2011 John Wiley & Sons, Ltd.
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clinical trials; and (6) review the available therapeutic
approaches to CAN.
Methodology
The CAN Subcommittee addressed these issues using
the following methods: (1) extensive literature search
(Appendix S1); (2) applying a defined system for rating
the levels of evidence and strengths of recommendations;
(3) preparation of a shared preliminary evidence-based
referenced report to be discussed during a 2-day Consen-
sus Meeting (held in Toronto); and (4) development of
this final document.
The methodology adopted for rating the quality of
evidence and strength of recommendations was that
suggested by the American Academy of Neurology [4]
for diagnostic studies and by the American College of
Cardiology and the American Heart Association Task
Force on Practice Guidelines [5] for therapeutic studies
(Appendix S1).
Definition of CAN
CAN is defined as the impairment of autonomic control
of the cardiovascular system in the setting of diabetes
after exclusion of other causes [6]. CAN is usually doc-




The reported prevalence of CAN varied greatly depending
on the tests, the diagnostic criteria used, the use of age-
related normative values, and the population studied. In
clinic-based studies in unselected populations, including
both type 1 and type 2 diabetic patients, the prevalence of
confirmed CAN (based on at least two abnormal cardio-
vascular heart rate test results) varied from 16.6 to 20%
[8,9].
Prevalence rates, however, increased both with age
(up to 38% in type 1 and 44% in type 2 patients aged
40–70 years) and diabetes duration (up to 35% in type 1
and 65% in type 2 patients with long-standing diabetes)
[10,11]. Abnormal CART results were present at the time
of diagnosis in about 7% of both type 1 and type 2 patients
[2]. The available longitudinal studies indicated an annual
increase in prevalence of CAN of about 6% in type 2
diabetes and of about 2% in type 1 diabetes [2,11,12].
Predictors and clinical correlates
In addition to age and diabetes duration, other diabetes-
related clinical correlates or predictors of CAN (as doc-
umented in cross-sectional or longitudinal studies) were
glycaemic control, the presence of diabetic polyneuropa-
thy, diabetic retinopathy, microalbuminuria or diabetic
nephropathy, and renal failure [2,3,9,10,13].
The role of several cardiovascular risk factors has also
been increasingly reported: blood pressure or hyper-
tension, smoking (only in cross-sectional studies), low-
density lipoprotein cholesterol, high-density lipoprotein
cholesterol, triglycerides, body weight or obesity in type
2 diabetes (with some controversy), waist circumference,
insulin levels in type 2 diabetes, cardiovascular disease,
and use of anti-hypertensive drugs [2,3,10,13]. Data on
the relationship between gender and CAN was controver-
sial (see also Appendix S2).
Conclusions
Establishing the prevalence of CAN is hampered by
heterogeneous and inadequate diagnostic criteria and
population selection. The prevalence of confirmed CAN
in unselected people with type 1 and type 2 diabetes is
around 20%, but figures as high as 65% are reported
with increasing age and diabetes duration. Because many
studies were hospital based, referral bias cannot be
excluded (classes II and III).
Clinical correlates or risk markers for CAN are
age, diabetes duration, glycaemic control, microvascular
complications (peripheral polyneuropathy, retinopathy,
and nephropathy), hypertension, and dyslipidaemia
(classes I and II).
Established risk factors for CAN are glycaemic control
in type 1 diabetes (class I), and a combination of
hypertension, dyslipidaemia, obesity, and glycaemic
control in type 2 diabetes (class II).
Recommendation
Suitable candidates for CAN screening are asymptomatic
type 2 diabetic patients at diagnosis and type 1 diabetic
patients after 5 years of disease, in particular those at
greater risk for CAN due to a history of poor glycaemic
control (haemoglobin A1c > 7%), or the presence of one
major cardiovascular risk factor (among hypertension,
dyslipidaemia, and smoking), or the presence of macro-
or microangiopathic complications (level B).
CAN screening may be also required in asymptomatic
patients for pre-operative risk assessment before major
surgical procedures (level C).
Clinical impact of CAN
Clinical manifestations of CAN
Symptomatic manifestations of CAN include sinus tachy-
cardia, exercise intolerance, and orthostatic hypotension.
Orthostatic hypotension was present in 6–32% of diabetic
patients depending on diagnostic cut-offs for fall in systolic
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Table 1. Abnormalities associated with cardiovascular
autonomic neuropathy at the level of cardiovascular















Dysregulation of cerebral circulation
⇓ Sympathetically mediated vasodilation of coronary vessels
↑ Arterial stiffness
Peripheral vascular function
↑ Peripheral blood flow and warm skin
↑ Arteriovenous shunting and swollen veins
↑ Venous pressure
Leg and foot oedema
Loss of protective cutaneous vasomotor reflexes
Loss of venoarteriolar reflex with microvascular damage
↑ Transcapillary leakage of macromolecules
Medial arterial calcification
blood pressure (20 or 30 mmHg) and the diabetic popu-
lations studied [2,9,10,14–16]. Symptoms of orthostatic
intolerance were present in 4–18% of diabetic patients
[9,15]. Orthostatic symptoms, such as light-headedness,
dizziness, blurred vision, fainting, or pain in the neck
or shoulder when standing, may be worse in the early
morning, after meals, during a rise in core temperature,
during prolonged standing, or with activity [16]. Symp-
toms may be disabling, are often a barrier to an effective
anti-hypertensive treatment, and may lead to falls in the
elderly.
A number of other cardiovascular abnormalities were
found in association with CAN [17,18]. These may play a
role in excess mortality and morbidity and contribute to
the burden associated with CAN (Table 1).
CAN and mortality
A meta-analysis of 15 longitudinal studies, which included
a total of 2900 patients followed up for 1–16 years,
showed that the diagnosis of CAN based on at least two
abnormal CART results determined a relative risk of mor-
tality of 3.65 (95% confidence interval 2.66–4.47) [17].
Subsequent studies confirmed the predictive value of CAN
on mortality [19–24] (Table 2). These studies provided
even stronger support that CAN is an independent pre-
dictor of mortality corrected for multiple confounding
factors (including cardiovascular risk factors). Moreover,
the pooled relative risk of mortality in clinic-based studies
that used more than one index was considerably higher
than in studies that used only one [17,22].
In diabetic patients the presence of orthostatic hypoten-
sion impaired the prognosis and increased the mortality
rate over that associated with vagal cardiac test abnormal-
ities [17]. Tachycardia was associated with total and/or
cardiovascular mortality in the diabetic population as well
as in the general, cardiac or hypertensive population [25].
There is also strong evidence, based on 12 out of 13
studies in 1319 patients with type 1 diabetes and 3396
patients with type 2 diabetes with a mean follow-up
of 9.2 years, that QT interval (QTi) prolongation is an
independent predictor of mortality for all-cause and car-
diovascular deaths [17,18,21,26] (see also Appendices S4
and S5).
CAN as a predictor of cardiovascular
morbidity
An association between CAN and silent myocardial
ischaemia (SMI) is well documented [2,27]. In a meta-
analysis of 12 studies including 1468 diabetic patients,
SMI was present in 20% of those with CAN compared
with 10% of those without CAN with a prevalence rate
ratio of 1.96 (95% confidence interval 1.53–2.51) [2]. At
baseline, the Detection of Ischaemia in Asymptomatic
Diabetics (DIAD) study showed that in 1123 type 2
diabetic patients the lowest quartile of the Valsalva ratio
was the strongest determinant of SMI, which was defined
as abnormal stress adenosine Tc-99m sestamibi Single
Photon Emission Computed Tomography myocardial
perfusion imaging [28]. Over a mean follow-up of
4.8 years, the lowest quartile of lying-to-standing test
was associated with an adjusted hazard ratio of 4.33
(95% confidence interval 2.14–8.75) for cardiac death or
non-fatal myocardial infarction [27].
CAN was reported to be a predictor of cardiovascular
morbidity and mortality in type 1 diabetes [20] and to
provide prognostic information for death and/or cardiac
events incremental to that offered by perfusion defects or
by the presence of SMI [29].
Moreover, CAN was associated with left ventricular
systolic and particularly diastolic dysfunction in the
absence of cardiac disease [18,30]. However, it is difficult
to evaluate the independent role of CAN in these disorders
and in chronic heart failure, as other factors such
as interstitial myocardial fibrosis, microangiopathic or
metabolic changes may also be responsible for diabetic
heart muscle disease and left ventricular dysfunction.
Four longitudinal studies documented that CART
abnormalities or QTi prolongation [18] imposes a twofold
risk of stroke. In the Pittsburgh Epidemiology of Diabetes
Complications study, CAN was associated with increased
arterial stiffness in type 1 diabetic patients 18 years later
[31].
Increased risk for perioperative morbidity and mortality
is well described in diabetes, and in seven out of
eight studies CAN was associated with haemodynamic
instability during general anaesthesia, cardiorespiratory
arrests, and abnormal cardiovascular reactions even
Copyright  2011 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2011; 27: 639–653.
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during minor surgery [18,32] (see Appendix S5 for
references).
Attenuation (non-dipping) or complete loss of the
nocturnal fall in blood pressure (reverse dipping) in
diabetes was associated with left ventricle hypertrophy
in cross-sectional studies or two- to eight-fold increase in
risk of cardiovascular or renal events in some longitudinal
studies [2,18].
CAN as a promoter of nephropathy
progression
Several studies (with one exception) showed that CAN
and autonomic pupillary abnormalities independently
predicted the progression of diabetic nephropathy [20].
It was suggested that this could be mediated by CAN-
induced changes in glomerular haemodynamics and in
the circadian rhythms of blood pressure and albuminuria.
Moreover, erythropoietin-deficiency anaemia and early
dysregulation of erythropoietin production have been
described in patients with CAN [33] as in different dysau-
tonomic conditions. Anaemia is a predictor of nephropa-
thy progression and erythropoietin exerts direct reno-
protective effects. Thus, both anaemia and erythropoietin
deficit may contribute to kidney damage in diabetes. Rest-
ing heart rate was reported to be associated with overt
nephropathy development in type 1 diabetic patients. In
the Atherosclerosis Risk in Communities (ARIC) study
in 13 241 adults (1523 with diabetes) followed up for
16 years, higher resting heart rate and lower heart rate
variability (HRV) indices were associated with the highest
risk of developing end-stage renal disease [34].
Moreover, non-dipping and reverse dipping were found
to predict, independent of 24-h blood pressure level,
the progression from overt nephropathy to renal failure
or dialysis in type 2 patients and – with some contro-
versy – the development of microalbuminuria in type 1
patients (see Appendix S5 for references).
Conclusions
There is definitive evidence for a predictive value of CAN
on overall mortality (class I).
There is some evidence for a predictive value of CAN
on morbidity (class II).
Orthostatic hypotension, when due to advanced CAN,
is associated with an additional increase in mortality risk
over that driven by HRV abnormalities (class III).
Some cardiovascular abnormalities, closely linked to
CAN, are associated with increased mortality: tachycardia
(class II), QTi prolongation (class II), and non-dipping
status (class III).
Recommendations
CAN is a risk marker of mortality (level A) as well as
a risk marker and likely a risk factor for cardiovascular
morbidity (level B), and possibly a progression promoter
of diabetic nephropathy (level C).
Orthostatic hypotension is associated with a worse
prognosis than cardiovagal neuropathy (level C).
QTi prolongation has prognostic value in diabetes (level
B). Non-dipping status is associated with an adverse
cardiovascular prognosis in diabetes (level C).
Non-dipping status predicts the progression from micro-
and macroalbuminuria to renal failure in type 2 diabetes
(level C).
CAN assessment
Methods of CAN assessment in clinical practice include
assessment of symptoms and signs, CARTs based on heart
rate and blood pressure, and ambulatory blood pressure
monitoring (ABPM).
Assessment of symptoms
Questionnaires have been developed to investigate ortho-
static symptoms and their severity in dysautonomic con-
ditions, although they have not been specifically validated
for CAN and validated translations in different languages
are lacking. In the Rochester Diabetic Neuropathy Study
the correlation between the autonomic symptoms and the
autonomic deficits was weak in type 1 and absent in type 2
diabetic patients [10]. Orthostatic symptoms were poorly
related to fall in systolic blood pressure on standing [35].
For their clinical impact, orthostatic symptoms should be
looked for regularly together with other dysautonomic
symptoms in diabetic patients.
Assessment of signs
Some clinical findings observed during routine clinical
evaluation or obtained as incidental data in clinical tests
as electrocardiography or ABPM can alert the physician
on the presence of CAN.
Tachycardia. Resting heart rate is a straightforward and
readily available clinical measurement. Tachycardia may
reflect diabetic autonomic dysfunction [18]. It can also
reflect vagal impairment and/or sympathetic overactivity
present in cardiac diseases, poor fitness, obesity, or
anaemia.
Emerging evidence on the prognostic value of heart
rate have led to the advice in the current hypertension
guidelines to measure heart rate in clinical practice [36]
and to use it for cardiovascular risk stratification and as
therapeutic target in high-risk patients [25,36].
Exercise intolerance. In diabetic patients without
evidence of heart disease, but with asymptomatic cardiac
vagal neuropathy, exercise capacity and heart rate,
blood pressure, and cardiac stroke volume responses to
exercise were diminished. A further decrease in exercise
capacity and blood pressure response was seen in patients
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with both vagal neuropathy and orthostatic hypotension.
The severity of CAN correlated inversely with maximal
heart rate increase during exercise [37], suggesting CAN
contribution to diminished exercise tolerance.
Orthostatic hypotension may result from various patho-
physiological conditions and is affected by drugs, hypo-
volaemia, and deconditioning. Orthostatic hypotension is
defined as a reduction of systolic blood pressure of at least
20 mmHg or diastolic blood pressure of at least 10 mmHg
within 3 min of standing [38,39] and a fall in systolic
blood pressure of 30 mmHg [35,40].
The presence of orthostatic hypotension after exclusion
of other causes suggests advanced CAN that should be
confirmed by CARTs. For its ease and prognostic value,
orthostatic hypotension should be assessed routinely in
diabetic patients even without symptoms, in particular
after the age of 50 [36].
QTi prolongation. QTi prolongation has been defined
as a QTc (corrected QT for heart rate) ≥460 ms in
women and ≥450 ms in men, although in most studies
less strict criteria were used. The pathogenesis of QTi
prolongation is multifactorial and includes imbalance
in cardiac sympathetic innervation, intrinsic metabolic
and electrolytic myocardial changes, left ventricular
hypertrophy, coronary artery disease (CAD), and genetic
factors [26].
The day–night modulation of the QT/relative risk
relation – on 24-h electrocardiogram recordings – was
altered in CAN patients free of coronary artery disease, left
ventricular dysfunction, or hypertrophy, with a reversed
day–night pattern and an increased nocturnal QT rate
dependence [41].
Reversible QTi prolongation may be induced by
hyperinsulinaemia in healthy subjects, by hyperglycaemia
[42] and by acute hypoglycaemia in both healthy and
diabetic subjects [26]. In type 1 diabetic patients,
prolonged QTc was shown to occur frequently during
overnight hypoglycaemia and to be associated with
cardiac rate/rhythm disturbances. These findings support
an arrhythmic basis for the ‘dead in bed’ syndrome and
possibly a provocative role in cardiovascular events of
hypoglycaemia-induced sympathetic activation [43].
In a meta-analysis of 17 studies including 4584 diabetic
patients, QTc prolongation (>441 ms) was a specific
(86%) albeit insensitive (28%) index of CAN [44].
Non-dipping and reverse dipping. ABPM is a standard
tool in hypertension research and management with
regard to diagnostic, prognostic, and therapeutic issues
[36]. It allows the assessment of the diurnal blood pres-
sure pattern, which is mainly regulated by sleep–awake
changes in the autonomic cardiovascular function. ABPM
may be used for research purposes to (1) evaluate the
circadian blood pressure pattern and its abnormalities
(e.g. non-dipping, nocturnal hypertension, extreme dip-
ping, morning surge); (2) study its relationship with
autonomic dysfunction, sleep disturbances, and kidney
function; (3) assess the 24-h blood pressure response to
treatment; and (4) evaluate the longer term prognostic
implications of circadian blood pressure abnormalities.
Non-dipping and reverse dipping patterns were associ-
ated with CAN, which was the major determinant of the
circadian variation in blood pressure. Several observa-
tions in both diabetic and non-diabetic patients linked
non-dipping to a disruption of the circadian variation in
sympathovagal activity, i.e. a diminished increase in vagal
activity and a sympathetic predominance during the night
[45]. The day–night difference in systolic blood pressure
was a moderately accurate diagnostic tool for CAN, and
reverse dipping as a specific (95%) – albeit insensitive
(25%) – marker of CAN [46]. In clinical practice, ABPM
in the general population is useful for diagnostic purposes
and provides unique and additional information for risk
stratification with regard to hypertension-related organ
damage and cardiovascular events, and for the extent of
blood pressure response to treatment [36]. The European
Society of Hypertension acknowledges that ABPM may
improve predictions of cardiovascular risk in hyperten-
sive patients and recommends that 24-h ABPM should be
considered in the presence of either noticeable variability
of office blood pressure values or a marked discrepancy
between office and home blood pressure values, and in
case there is resistance to drug treatment or hypoten-
sive episodes are suspected [36]. Thus, in patients with
CAN, ABPM may be particularly useful in detecting non-
dipping or reverse dipping conditions, daytime postural
blood pressure changes, and postprandial hypotension,
and in achieving blood pressure control for the whole
24-h period. Conversely, in clinical practice, the presence
of reverse dipping in ABPM may suggest the presence of
CAN and thus requires CAN testing (see Appendix S5 for
references).
Conclusions
Resting heart rate is not a specific sign of CAN (class IV).
After exclusion of other causes orthostatic hypotension
suggests an advanced CAN that should be confirmed by
CARTs (class I).
Orthostatic hypotension (class III), QTi prolongation
(class II), and reverse dipping on ABPM are specific but
insensitive indices of CAN (class III).
Recommendations
The presence of symptoms and/or signs is not a sufficient
criterion for CAN diagnosis but should provide the
motivation to perform CAN testing to get a definite
diagnosis (level B).
Screening of orthostatic symptoms is advisable in any
diabetic patient (level B).
Regardless of the presence of orthostatic symptoms,
the orthostatic hypotension test is recommended yearly,
in particular in patients over the age of 50 and in
hypertensive diabetic patients (level B).
CAN testing offers a useful tool to identify patients with
potentially poor exercise performance and to prevent
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adverse outcomes when patients are introduced to
exercise training programs (level C).
Diabetic patients with unexplained tachycardia should
undergo CAN testing (level C).
Resting heart rate may be used in clinical practice for
cardiovascular risk stratification (level C).
QTi prolongation alone is an insufficient measure of
CAN but should prompt further testing (level B).
QTc may be used for cardiovascular risk stratification
(level B).
ABPM should not be routinely employed for the
diagnosis of CAN (level C). However, it is a reliable
research tool to explore 24-h blood pressure patterns in
different conditions (level B).
In the presence of reverse dipping, referral for CAN
testing is advisable (level C).
ABPM may be useful in patients with CAN to detect non-
dipping, to determine risk stratification for cardiovascular
mortality and nephropathy progression, and to adjust
anti-hypertensive treatment (level C).
Cardiovascular autonomic reflex tests
CARTs assess cardiovascular autonomic function through
provocative physiological manoeuvres and by measur-
ing the end-organ response, i.e. heart rate and blood
pressure changes. Although indirect autonomic measures,
they are considered the gold standard in autonomic test-
ing. Heart rate variations during deep breathing, Valsalva
manoeuvre, and lying-to-standing (heart rate tests) are
indices mainly of parasympathetic function, whereas the
orthostatic hypotension, the blood pressure response to
a Valsalva manoeuvre and sustained isometric muscular
strain provide indices of sympathetic function [1,7,14].
These tests are non-invasive, safe, clinically relevant (they
correlate with tests of peripheral nervous system func-
tion), easy to perform, sensitive, specific, reproducible,
and standardized, and therefore they are considered con-
solidated, gold-standard measures of autonomic function
[7]. Blood pressure response to sustained handgrip is no
longer regarded as an established clinical test but as an
investigational test [7], whereas the orthostatic hypoten-
sion test still represents an essential part of the standard
assessment of CAN, despite its low sensitivity [35].
Valsalva manoeuvre increases intrathoracic, intraocu-
lar, and intracranial pressure and may theoretically be
associated with a small risk of intraocular haemorrhage
or lens dislocation [7]. In the absence of data on the
occurrence of retinal complications induced by CARTs,
avoiding the Valsalva manoeuvre in patients with prolif-
erative retinopathy may be appropriate [35].
There is no statistical evidence of a striking superiority
in diagnostic characteristics of a cardiovascular heart rate
test over the others [18]. It is also worthy of consid-
eration that (1) the deep breathing test is certainly the
most widely used test; (2) the Valsalva manoeuvre needs
greater cooperation from patients and cannot be univer-
sally performed, and heart rate response depends on the
blood pressure response to the manoeuvre; and (3) the
orthostatic hypotension test is affected by a number of
confounding factors [35].
CARTs have a number of confounding factors [35].
Table 3 contains a list of these confounders with
corresponding recommendations (see also Appendix S3).
Diagnosis and staging of CAN
How many and which tests
to use for diagnosis?
There is no evidence that one individual heart rate test
may substitute for the other two, or have such a clear
diagnostic superiority as to be used on its own [4]. More-
over, the diagnostic definition of CAN based on several
tests reduces the probability of false positives. The need to
use several tests of both vagal and sympathetic functions
is reaffirmed in the available guidelines [1,3].
The prognostic value of CAN for mortality and cardio-
vascular events differs according to the number of tests
used for its diagnosis [17,18,47]. The number of abnor-
mal results most likely represents an indication of severity
or progression of the disease and affords a more robust
definition of CAN.
Test abnormalities should be defined using age-based
and technique-specific normative data (see Table 3 and
Appendix S3) [35].
Diagnostic criteria for CAN
No unanimous criteria for diagnosis of CAN have been
adopted to date. A single abnormal result among the two
or three heart rate tests actually performed was consid-
ered a sufficient criterion for early CAN diagnosis [1–3].
However, the presence of abnormalities in more than
one test on several occasions was indicated as preferable
for diagnosis [1]. In addition, the presence of two or
three abnormal results (two for borderline, three for def-
inite) among the seven autonomic cardiovascular indices
(including the five standard CARTs and other time and
frequency domain indices of HRV) was recommended as
a criterion for CAN diagnosis [8].
Staging of CAN
Ewing et al. originally proposed a classification based on
‘early involvement’ (one abnormal result on heart rate test
or two borderline results), ‘definite involvement’ (two or
more abnormal results on heart rate tests), and ‘severe
involvement’ (presence of orthostatic hypotension) [14].
An ‘autonomic neuropathy score’ – obtained by scoring the
results of CARTs – has been used with the dual advantage
of quantifying the progression of CAN and providing an
overall quantitative result [35].
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Table 3. Confounding factors on cardiovascular autonomic testing
Physiological confounders Advice Recommendation
Standardization Follow the standard procedures in
performing tests and control or
minimize the influence of
confounding factors
Standardization of testing procedure
and control of confounding factors
are essential to the reliability of
cardiovascular tests
Patients’ compliance Provide detailed information to the
subject
Instructions to patients and their
familiarization with the tests allow a
better standardization of stimuli
Age Use normal age-related values Age-related normal reference values
are strictly required to correctly
interpret the results of all the heart
rate-based cardiovascular tests (level
B)
Respiratory pattern Control for respiratory pattern Accurate instruction on timed deep
breathing and on avoidance of deep
or irregular breaths after the
Valsalva manoeuvre and after
standing is advisable (level C)
Body position Allow a sufficient supine rest
before orthostatic test
Adequate supine rest before standing
is necessary to increase
reproducibility and test reliability
Basal heart rate and blood pressure Caution in interpreting the results
of heart rate tests with a resting
heart rate >100 bpm and of
orthostatic hypotension test with
supine systolic blood pressure
>160 mmHg or <120 mmHg
No correction is needed for the resting
heart rate (level C), the possible
confounding effect of supine
systolic blood pressure should be
taken into account when evaluating
orthostatic hypotension test (level B)
Physical exercise Avoid strenuous exercise 24 h
before testing.
Patients should be requested to avoid
strenuous physical exercise in the
24 h preceding the tests
Coffee, alcohol, smoking Avoid consumption of coffee and
alcohol, and smoking before
testing
Patients should be requested to avoid
caffeine beverages, smoking, and
alcohol at least 2 h prior to the tests
Meals Avoid testing just after main meals It is advisable to perform the tests at
least 2 h after a light meal
Pathophysiological confounders
Intercurrent diseases Avoid testing in the presence of
intercurrent diseases associated
with fever, infection, or
dehydration
It is advisable to avoid testing during
acute disease, stressful condition,
fever, infection, dehydration
Hypoglycaemia, hyperglycaemia Avoid testing during
hypoglycaemia or marked
hyperglycaemia
Tests should not be performed during
hypoglycaemia or marked
hyperglycaemia (level C)
Insulin Avoid testing just after short-acting
insulin administration
Tests should be performed at least 2 h
after short-acting insulin
administration (level C)
Respiratory and cardiovascular disease Control for associated diseases Test results should be interpreted with
caution in presence of respiratory or
cardiovascular diseases, in particular
heart failure (level C)
Drugs Control for medications An appropriate wash-out of
interfering drugs, particularly
diuretics, sympatholytic agents and
psychoactive drugs should be
pursued, if not feasible, results
should be interpreted with caution
While an abnormal orthostatic hypotension test result
generally occurs late in diabetes and subsequent to abnor-
malities in the heart rate tests, no chronological order or
a markedly different prevalence of abnormalities among
the heart rate tests has been found [8,35]. Considering
progression from an early to an advanced involvement,
instead of from parasympathetic to sympathetic neuropa-
thy, would appear to be the most appropriate approach to
CAN staging (Figure 1), although orthostatic hypotension
may on rare occasions precede abnormalities in heart rate
tests [2,14,35]. The available information regarding the
duration required to progress from an earlier to a later
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Figure 1. Stages of cardiovascular autonomic neuropathy
stage of CART impairment is scant and it is not docu-
mented that a progression to orthostatic hypotension and
symptomatic forms invariably occurs in all patients.
The combination of CARTs with tests for sudomotor
function may provide a more accurate diagnosis of
diabetic autonomic neuropathy [4].
Conclusions
The following CARTs are the gold standard for clinical
autonomic testing: heart rate response to deep breathing,
standing, and Valsalva manoeuvre, and blood pressure
response to standing (class II) (Table 4).
These CARTs are sensitive, specific, reproducible, easy
to perform, safe, and standardized (classes II and III).
The Valsalva manoeuvre is not advisable in the pres-
ence of proliferative retinopathy and when there is an
increased risk of retinal haemorrhage (class IV).
CARTs are subject to a number of confounding or inter-
fering factors (class III). Age is the most relevant factor
affecting heart rate tests (class I).
A definite diagnosis of CAN and CAN staging requires
more than one heart rate test and the orthostatic hypoten-
sion test (class III).
Recommendations
Diagnosis of CAN is based on the use of CARTs for
heart rate response to deep breathing, standing, Valsalva
manoeuvre, and for blood pressure response to standing
(level A).
For the diagnosis and monitoring of CAN, more than
one heart rate test and the orthostatic hypotension test
are required (level B).
Performance of CARTs should be standardized and the
influence of confounding variables minimized (level A).
Age-related normal ranges of heart rate tests are strictly
required (level A).
CAN diagnosis and staging: (1) the presence of one
abnormal cardiovagal test result identifies the condition
of possible or early CAN, to be confirmed over time; (2) at
least two abnormal cardiovagal results are required for
a definite or confirmed diagnosis of CAN; and (3) the
presence of orthostatic hypotension in addition to heart
rate test abnormalities identifies severe or advanced CAN
(level B).
CARTs allow CAN staging from early to advanced
involvement (level C).
Progressive stages of CAN are associated with increas-
ingly worse prognosis (level B).
Usefulness of CAN diagnosis
in clinical practice
The detection of CAN may help tailor
therapeutic strategies for patients
with diabetes
For instance it may help in the individualized treatment
of orthostatic hypotension, tachycardia, non-dipping and
nocturnal hypertension [25]. In the presence of CAN,
blood pressure should not be measured only in the seated
position when adjusting anti-hypertensive treatment
(particularly in patients with orthostatic hypotension);
and drugs with adverse autonomic consequences should
be avoided. Drugs with the potential to prolong QTi
should be avoided where possible in patients with CAN.
CAN testing and exercise program
Given the association between CAN and symptoms of
exercise intolerance, decreased cardiac responsiveness to
exercise and exercise-induced orthostatic hypotension,
the estimate of exercise intensity should be based on
ratings of perceived exertion scale rather than heart rate
increase in CAN patients [18]. Therefore, CAN testing
should be considered before a stress exercise test.
Testing should also be considered before beginning a
program of more vigorous physical activity than brisk
walking. The presence of severe CAN may contraindicate
certain types of exercise or predispose patients to injury
[48].
CAN testing for the evaluation
of perioperative anaesthetic risk
CAN may be considered as a risk marker for anaesthetic
haemodynamic instability thus highlighting the need for
a careful haemodynamic monitoring during the operative
and perioperative periods [32] (see Appendix S5 for
references).
CAN testing for risk stratification
for morbidity and mortality
CAN is a risk marker for all-cause and cardiac
mortality, for stroke, coronary events, SMI, heart failure,
arrhythmia, sudden death, and nephropathy progression
[2,17,18,27–30,33,34].
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Table 4. Cardiovascular autonomic tests and suggested indications for their use




Orthostatic hypotension test Yes Yes No (low sensitivity)
QT interval Yes (additional information and
risk stratification)




Yes (risk stratification) Yes No (low sensitivity)
Heart rate variability time
and frequency domain
indices





No (early additional information
and risk stratification but low
availability)
Yes Yes





No (low availability, limited data in
cardiovascular autonomic
neuropathy)
Yes Possible (used in lifestyle
intervention trials in obesity)
Catecholamine assessment No (low availability) Yes Possible (used in lifestyle
intervention trials in obesity)
CAN testing for risk stratification
before screening for CAD
In light of recent data [27], generalized and routine
screening for CAD in asymptomatic type 2 patients no
longer appears to be justified, whereas testing for SMI and
silent coronary stenoses should be performed exclusively
for individuals at very high risk [49].
CAN may play a pivotal role in the identification of
these high-risk diabetic patients for its association with a
twofold risk for SMI [2] and its predictive value on cardiac
events [27–29]. Thus, CAN testing may be considered a
main component of a diabetes-specific risk pattern to
identify high-risk subjects in whom CAD screening is
more effective [49]. CAN testing may also improve patient
adherence to risk-reducing therapies [49].
CAN testing for risk stratification
for sudden death following myocardial
infarction
Type 2 diabetes is associated with a twofold to fourfold
increase in the risk of sudden cardiac death (SCD)
in particular after a myocardial infarction. CAD is
the most common pathologic substrate for SCD in
adults. Ventricular fibrillation is the most common
electrophysiological mechanism, with impaired cardiac
autonomic modulation considered as a key factor in the
development of a cardiac arrest [50]. Some autonomic
indices, i.e. HRV, baroreflex sensitivity, heart rate
turbulence, deceleration capacity, heart rate recovery
after exercise, were independent predictors of cardiac
death after myocardial infarction, with better predictive
value when used in combination [50]. However, it has
not been proved that any of them can effectively identify
patients likely to benefit from prophylactic therapy with
implantable cardioverter defibrillator [50].
Robust and conclusive data assessing the predictive
value of HRV for SCD after myocardial infarction in
diabetic patients is still lacking [51]. A risk stratification
scheme for the prevention of SCD in diabetic patients has
not yet been identified [51], and the role of CAN testing
in SCD risk stratification needs to be clarified.
CAN testing to define the target
of glycaemic control
Hypoglycaemia has a proarrhythmogenic effect through
QTi prolongation, attenuation of cardiovagal baroreflex
function [52], and Ca2+ overload consequent to sym-
pathetic activation. Diabetes and cardiovascular disease
contribute to both changes [53]. Although definitive
evidence that hypoglycaemia can be regarded as a proar-
rhythmogenic event leading to malignant ventricular
tachyarrhythmias and SCD does not exist, there are indica-
tions of an association between hypoglycaemia and SCD,
in particular in patients with cardiac disease [54,55].
The role of CAN in this setting is still undefined. Severe
CAN may attenuate the sympathetic response to hypogly-
caemia and is also associated with QTi prolongation and
baroreflex impairment which may predispose to cardiac
death. In the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study, although self-reported history
of neuropathy was associated with an increased mortal-
ity risk in the group on intensive diabetes therapy, the
presence of abnormal autonomic indices derived from a
resting electrocardiogram (CARTs were not formally per-
formed) did not account for the difference in mortality
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rate between intensive and standard glycaemia treatment
groups [24].
The presence of CAN may identify diabetic patients
more prone to the dangerous effects of hypoglycaemia, in
particular among the group with cardiac disease. Thus,
CAN testing may serve to define the target of glycaemic
control according to the patient’s risk profile and also to
weigh up the advantage of aggressive diabetes treatment
against the risk. However, it is still unproven that the
presence of CAN should be a contraindication for intensive
glycaemic control.
CAN testing to overcome clinical
inertia and patient non-adherence
The presence of CAN may promote a proactive behaviour
in health providers and patients, although this is
unproven.
Likewise, there is a lack of prospective studies that
assess the cost-effectiveness of CAN testing in the
asymptomatic stages of CAN, the impact of therapeutic
changes on ultimate or surrogate endpoints as a
consequence of CAN diagnosis, and which patients could
benefit most from CAN testing.
Conclusions
CAN assessment is relevant in clinical practice for
• Diagnosis of symptomatic and clinical forms of CAN
and explaining symptoms suggestive of diabetic
dysautonomia (classes II and III);
• detection and tailored treatment in the presence
of CAN clinical correlates: tachycardia, ortho-
static hypotension, non-dipping, QTi prolongation
(classes III and IV);
• risk stratification for diabetes-related complications
(class III);
• risk stratification for cardiovascular morbidity and
mortality (classes II and III); and
• tailoring of targets of diabetes therapy (class IV).
There is a lack of prospective studies assessing the
cost-effectiveness of CAN testing.
Recommendations
In symptomatic and clinical forms of CAN, diagnosis may
allow a directed treatment of the clinical consequences of
CAN and may provide insight into the general therapeutic
strategy in diabetic patients (level B).
In asymptomatic patients, CAN assessment may be
required for the evaluation of perioperative risk (level C).
In asymptomatic patients, CAN assessment may be used
for cardiovascular risk stratification (level C).
CAN may be assumed to be a component of a diabetes-
specific risk pattern to identify high-risk diabetic subjects
in whom screening for CAD is cost effective (level U).
CAN diagnosis may serve to modulate targets of
therapeutic intervention and to address clinical inertia
and foster patient adherence (level U).
CAN diagnosis may be useful if followed by a
modification of disease management and/or therapeutic
strategies.
Management of CAN
Glycaemic control and multifactorial
risk intervention
In the Diabetes Control and Complications Trial (DCCT)
study intensive insulin treatment in type 1 diabetic
patients reduced the incidence of CAN by 53% compared
to conventional therapy [12]. In the Epidemiology of
Diabetes Interventions and Complications (EDIC) study,
at the 13th–14th year after DCCT closeout, although
CAN progressed substantially in both treatment groups,
its prevalence and incidence remained significantly lower
in the former intensive than in the former conventional
group [11], supporting that intensive treatment of type 1
diabetes should be initiated as early as is safely possible.
In the Steno 2 study, an intensive multifactorial
cardiovascular risk intervention reduced the progression
or the development of CAN among type 2 diabetic patients
with microalbuminuria [56]. However, the beneficial
effect of intensive glycaemic control on CAN in type 2
diabetes has not been specifically proven [57].
Lifestyle modification
In the Diabetes Prevention Program, autonomic func-
tion indices improved in subjects with pre-diabetes
randomized to the lifestyle modification arm aimed at
weight reduction and at engaging physical activity [58].
Weight loss in obese patients is accompanied by improve-
ment in cardiovascular autonomic function [59]. A few
small – mostly open – interventional studies in diabetes
showed a beneficial effect for aerobic training on car-
diovascular autonomic indices, with some indication that
mild physical exercise may be effective only in patients
with less severe CAN.
Treatment based on pathogenetic
concepts
Only limited data on a pathogenetically oriented
pharmacotherapy are available in CAN patients [18].
Phase II randomized controlled trials have shown
favourable effects on HRV indices using the anti-oxidant
α-lipoic acid [60], vitamin E, and C-peptide. Further
studies are needed to confirm these findings as well as to
evaluate other potential pathogenetic treatments.
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Pharmacological modulation
of autonomic tone
A number of drugs may adversely affect the autonomic
tone by reducing HRV with consequent potential pro-
arrhythmic effect [61]. On the other hand, an increase
in HRV has been described – with some controversy – in
diabetic patients with angiotensin-converting enzyme
inhibitors, angiotensin II type 1 receptor blockers, car-
dioselective β blockers without intrinsic sympathomimetic
activity (e.g. metoprolol, nebivolol, bisoprolol), digoxin,
and verapamil [18,35,60]. Cardioselective β blockers can
be used to treat resting tachycardia associated with CAN.
Symptomatic treatment of orthostatic
hypotension
Treatment of orthostatic hypotension is required only
when symptomatic with the therapeutic goal to minimize
postural symptoms rather than to restore normotension.
The first step encompasses non-pharmacological measures
with the attempt to (1) identify other causes of orthostatic
hypotension, e.g. volume depletion, and avoid, when
possible, drugs exacerbating postural symptoms, such
as psychotropic drugs, diuretics, and α-adrenoreceptor
antagonists; (2) educate patients regarding behavioural
strategies such as gradual staged movements with postu-
ral change, mild isotonic exercise, head-up bed position
during sleep, physical counter-manoeuvres (e.g. leg-
crossing, stooping, squatting, and tensing muscles), use
of portable folding chairs, increased fluid and salt intake
if not contraindicated, drinking water rapidly, and avoid-
ance of large meals rich in carbohydrates; (3) use of
elastic garment over the legs and abdomen. If symptoms
persist despite these measures, a pharmacological treat-
ment should be considered. Several drugs have efficacy
in the treatment of neurogenic orthostatic hypotension
[39,61]. The potential risks of a drug should be weighed
against its possible benefit, including the balance between
the goal of increasing standing blood pressure and the
avoidance of a marked supine hypertension.
The peripheral selective α1-adrenergic agonist mido-
drine is a first-line drug that exerts a pressor effect
through both arteriolar constriction and venoconstriction
of the capacitance vessels. The dosing should be indi-
vidually tailored (up to two to four times 10 mg/day,
with the first dose taken before arising and use avoided
several hours before planned recumbency particularly in
patients with documented supine hypertension). Adverse
events are pilomotor reactions, pruritus, supine hyperten-
sion, bradycardia, gastrointestinal symptoms, and urinary
retention. Midodrine is the only medication approved by
the Food and Drug Administration for the treatment of
symptomatic orthostatic hypotension and is now under
reconsideration.
The 9-α-fluorohydrocortisone is another first-choice
drug that acts through sodium retention, a direct con-
stricting effect on partially denervated vessels, and an
increase in the water content of the vessel wall leading to
a reduced distensibility. Possible adverse effects include
supine hypertension, hypokalaemia, congestive heart fail-
ure, and peripheral oedema. The initial dose should be
0.05–0.1 mg daily with individual titration to 0.1–0.3 mg
daily [62].
Erythropoietin was proposed to increase standing
blood pressure via several mechanisms: (1) increasing
red cell mass and central blood volume, (2) correcting
the anaemia frequently associated with severe CAN, and
(3) neurohumoral effects on the vascular wall and vas-
cular tone regulation. It can be administered in diabetic
patients with haemoglobin levels under 11 g/dL subcuta-
neously or intravenously at doses between 25–75 U/kg
three times/week with an haemoglobin target of 12 g/dL
followed by lower maintenance doses [62].
Other possible treatments include (1) desmopressin
acetate, a vasopressin analogue useful to correct noc-
turnal polyuria and morning orthostatic hypotension;
(2) somatostatin analogues aimed at inhibiting the release
of vasoactive gastrointestinal peptides, enhancing cardiac
output, and increasing forearm and splanchnic vascular
resistance, with severe cases of hypertension as pos-
sible adverse events in diabetic patients; (3) caffeine
and (4) acarbose, both useful in attenuating postprandial
hypotension in autonomic failure [39,62].
Conclusions
Intensive diabetes therapy retards the development of
CAN in type 1 diabetes (level A).
Intensive multifactorial cardiovascular risk intervention
retards the development and progression of CAN in type
2 diabetes (level B).
Lifestyle intervention may improve HRV in pre-diabetes
(level B) and diabetes (level B).
Symptomatic orthostatic hypotension may be improved
by non-pharmacological measures (level B) and by
midodrine (level A) and/or fludrocortisone (level B).
Drug treatment of symptomatic orthostatic hypotension
in diabetic patients with CAN may be challenging and
should be thoroughly balanced between the goal of
increasing standing blood pressure and the avoidance
of a marked increase in supine blood pressure (level C).
Recommendations
Diabetes therapy in patients with type 1 and type 2
diabetes should consider the individual risk profile and
comorbidities (class I).
Lifestyle intervention should be offered as a basic
preventive measure (class I).
Given the limited evidence from very few large-
scale randomized clinical trials, recommendations cannot
be given for pharmacological and non-pharmacological
treatments of CAN.
Drugs that may reduce HRV should be avoided in
patients with CAN (class III).
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Resting tachycardia associated with CAN can be treated
with cardioselective β blockers (class I).
The first therapeutic approach in symptomatic ortho-
static hypotension should consider the exclusion of drugs
exacerbating orthostatic hypotension, correction of vol-
ume depletion (class I), and other non-pharmacological
measures (class IIa).
Pharmacotherapy of symptomatic orthostatic hypoten-
sion should include midodrine (class I) or fludrocortisone
or a combination of both in non-responders to monother-
apy (class IIa).
Because of the limited evidence, the potential risk of any
pharmacological treatment should be thoroughly weighed
against its possible benefit (class I).
CARTs should be used as end-points in prospective
observational and clinical trials.
Issues for future research
Longitudinal studies are needed (1) to clarify the natural
history of CAN, in particular in type 2 diabetes and pre-
diabetes; (2) to evaluate the impact of pharmacological
and lifestyle interventions targeting CAN; and (3) to
determine the effect of CAN on clinical outcomes and
its long-term prognostic relevance.
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